The three sites in Anagni, Italy, Brussels in Belgium, and Bloomington, Indiana, in the US will change hands “as soon as possible after the merger,” said Novo Nordisk, which has pledged to ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month.

The letter indicates that Novo Nordisk already has 55% of the market ... sites covered by the deal is located in the US – at Bloomington, Indiana – while the other two are at Anagni in Italy ...

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...